Function and therapeutic value of astrocytes in neurological diseases

HG Lee, MA Wheeler, FJ Quintana - Nature reviews Drug discovery, 2022 - nature.com
Astrocytes are abundant glial cells in the central nervous system (CNS) that perform diverse
functions in health and disease. Astrocyte dysfunction is found in numerous diseases …

Multiple sclerosis progression: time for a new mechanism-driven framework

T Kuhlmann, M Moccia, T Coetzee, JA Cohen… - The Lancet …, 2023 - thelancet.com
Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors—
relapsing-remitting, secondary progressive, and primary progressive—for patient care …

How patients with multiple sclerosis acquire disability

FD Lublin, DA Häring, H Ganjgahi, A Ocampo… - Brain, 2022 - academic.oup.com
Patients with multiple sclerosis acquire disability either through relapse-associated
worsening (RAW) or progression independent of relapse activity (PIRA). This study …

Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions

MP McGinley, JA Cohen - The Lancet, 2021 - thelancet.com
Summary The sphingosine 1-phosphate (S1P) signalling pathways have important and
diverse functions. S1P receptors (S1PRs) have been proposed as a therapeutic target for …

Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in …

L Kappos, JS Wolinsky, G Giovannoni… - JAMA …, 2020 - jamanetwork.com
Importance Accumulation of disability in multiple sclerosis may occur as relapse-associated
worsening (RAW) or steady progression independent of relapse activity (PIRA), with PIRA …

Secondary progressive multiple sclerosis: new insights

BAC Cree, DL Arnold, J Chataway, T Chitnis, RJ Fox… - Neurology, 2021 - AAN Enterprises
In most cases, multiple sclerosis (MS) begins with a relapsing-remitting course followed by
insidious disability worsening that is independent from clinically apparent relapses and is …

Progressive multiple sclerosis: from pathophysiology to therapeutic strategies

S Faissner, JR Plemel, R Gold, VW Yong - Nature reviews drug …, 2019 - nature.com
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that
involves demyelination and axonal degeneration. Although substantial progress has been …

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis

X Montalban, R Gold, AJ Thompson… - Multiple Sclerosis …, 2018 - journals.sagepub.com
Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming
available in the past years. There is a need for a reference tool compiling current data to aid …

Ocrelizumab versus placebo in primary progressive multiple sclerosis

X Montalban, SL Hauser, L Kappos… - New england journal …, 2017 - Mass Medical Soc
Background An evolving understanding of the immunopathogenesis of multiple sclerosis
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …

Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis

HYF Yong, VW Yong - Nature Reviews Neurology, 2022 - nature.com
In contrast to the multiple disease-modifying therapies that are available for relapsing–
remitting multiple sclerosis (MS), the therapeutic options for progressive MS (PMS) are …